Keyphrases
Aptamer
100%
Carbon Dots (C-dots)
100%
Hybrid Composites
100%
Vascular Disease
100%
Anti-vascular Endothelial Growth Factor (anti-VEGF)
100%
Topical Treatment
100%
Vascular Endothelial Growth Factor
80%
Cornea
20%
Nanomaterials
20%
Diabetic Retinopathy
20%
Commercially Available
20%
Controlled Release
20%
No Toxicity
20%
Hybrid Nanoparticles
20%
Angiogenesis
20%
Nanomedicine
20%
Ocular Diseases
20%
Carbon Modification
20%
Age-related Macular Degeneration
20%
Topical Administration
20%
Murine Animal Model
20%
Aflibercept
20%
Bevacizumab
20%
Therapeutic Levels
20%
Choroidal Blood Vessels
20%
Concentration Monitoring
20%
Back of the Eye
20%
Hybrid Carbon Materials
20%
Pharmacology, Toxicology and Pharmaceutical Science
Nanocomposite
100%
Vasculotropin
100%
Vascular Disease
100%
Aptamer
100%
Carbon Quantum Dot
71%
Nanomaterial
14%
Controlled Release
14%
Nanoparticle
14%
Age Related Macular Degeneration
14%
Eye Disease
14%
Bevacizumab
14%
Nanomedicine
14%
Diabetic Retinopathy
14%
Aflibercept
14%
Biochemistry, Genetics and Molecular Biology
Vascular Endothelial Growth Factor
100%
Aptamer
100%
Animal Model
14%
Angiogenesis
14%
Aflibercept
14%
Bevacizumab
14%
Chemical Engineering
Nanoparticle
100%
Nanomedicine
100%